CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionPrice-to-book is 0.98×, lower than 95% of its Biotechnology peers (median 2.91×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
316.69MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.3850xvs all stocks
52-Week Change
-65.56%vs all stocks
Market Capitalization
316.69MUSDvs all stocks (USD)
Enterprise Value
93.49MUSDvs all stocks (USD)
Forward P/E
-1.45xvs Biotechnology peers
Price to Book (MRQ)
0.9794xvs Biotechnology peers
Enterprise to EBITDA
-0.4710xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-47.11%vs Biotechnology peers
Return on Equity (TTM)
-81.92%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-198.65MUSDvs all stocks (USD)
Net Income (TTM)
-182.11MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-151.28MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-89.98MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-145.82MUSDvs all stocks (USD)
Pre-tax Income
-134.04MUSDFY2025 · Dec 31, 2025Net Income
-134.04MUSDFY2025 · Dec 31, 2025EBIT
-145.82MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-145.21MUSDFY2025 · Dec 31, 2025Research & Development
121.20MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
24.62MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.34MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-134.04MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-136.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
-137.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
373.82MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-134.04MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
610.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
5.87MUSDFY2025 · Dec 31, 2025Other Non-cash Items
725.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.84MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.88MUSDFY2025 · Dec 31, 2025Capital Expenditures
-606.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-83.92MUSDFY2025 · Dec 31, 2025Sale of Investments
157.86MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
73.33MUSDFY2025 · Dec 31, 2025Other Financing Charges
361.13MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
383.36MUSDFY2025 · Dec 31, 2025Shares Outstanding
80.12MSharesUpdated Sep 27, 2026Float Shares
35.81MSharesUpdated Sep 27, 2026Shares Short
3.60MSharesUpdated Sep 27, 2026Short Ratio
6.49daysvs all stocks
Short % of Shares Outstanding
12.60%vs all stocks
% Held by Insiders
27.13%vs all stocks
% Held by Institutions
71.00%vs all stocks
Total Cash (MRQ)
225.71MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.81USDUpdated Sep 27, 2026Total Debt (MRQ)
2.51MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0078xvs Biotechnology peers
Current Ratio (MRQ)
4.69xvs Biotechnology peers
Book Value per Share (MRQ)
4.03USDUpdated Sep 27, 2026Total Assets
448.38MUSDvs all stocks (USD)
Total Current Assets
432.40MUSDFY2025 · Dec 31, 2025Total Liabilities
37.28MUSDFY2025 · Dec 31, 2025Total Non-current Assets
15.98MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.24MUSDFY2025 · Dec 31, 2025Total Current Liabilities
35.04MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
373.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
51.77MUSDFY2025 · Dec 31, 2025Accounts Payable
1.37MUSDFY2025 · Dec 31, 2025Short-term Debt
522.00KUSDFY2025 · Dec 31, 2025Long-term Debt
2.24MUSDFY2025 · Dec 31, 2025Common Stock (Book)
8.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-356.57MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
411.10MUSDvs all stocks (USD)
52-Week Low
3.89USDUpdated Sep 27, 202652-Week High
14.87USDUpdated Sep 27, 202652-Week Change
-65.56%vs all stocks
Beta
0.3850xvs all stocks
50-Day MA
7.93USDUpdated Sep 27, 2026200-Day MA
9.32USDUpdated Sep 27, 2026Avg 10-Day Volume
678.32KSharesUpdated Sep 27, 2026Avg 30-Day Volume
568.30KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-2.27USDUpdated Sep 27, 2026Other Income / Expense
432.00KUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.98×, lower than 95% of its Biotechnology peers (median 2.91×)Notable
Price-to-book: 0.98Industry median: 2.91Industry P5: 0.99Peers compared: 258
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.59
Altman Z-Score 3.97: safe zoneNotable
Altman Z-Score: 3.97
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 35,820,060.775
Companies that share the same coordination system — how they create, deliver, or capture value.
Enwei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Green Cross Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Dishman Carbogen Amcis Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vanda Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CytoDyn Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
3 interpretationsDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
SuperX AI Technology Limited
3 interpretationsDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Directa Plus Plc
3 interpretationsDecline With Range Expansion And DrawdownCash Elevated Relative to Current Liabilities and Total AssetsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated